Csongrady A, Pfänder C
Prakt Anaesth. 1976 Dec;11(6):371-8.
A new sodium-nitroprusside-preparation (Nipruss) was tested in 40 patients for a controlled hypotension in neurosurgical as well as maxillary- and face-surgical operations. Differences between the phases of hypotension by Nipruss were pointed out for NLA, halothane- and enflurane-narcosis. An initial hypotension of -48 per cent, caused by Nipruss, was accompanied by an increase of the cardiac frequency of +33 per cent. This was dependent on the different methods of anaesthesia. The doses necessary for an average permanent hypotension of -36 per cent varied between 1.3 and 22.3mug/kg/min. The results proved, that Nipruss guarantees a diminished blood field even be used without head-up-position and at moderate hypotension. In combination with halothane and enflurane, hypotension could be regulated easier than with NLA. However, this resulted often in a higher frequencyload of the heart, so that frequently beta-adrenergic blocking drugs had to be administered. The operation conditions were improved, incidents did not occur. The new preparation Nipruss has organizational and hygienic advantages.
一种新型硝普钠制剂(Nipruss)在40例患者中进行了测试,用于神经外科手术以及上颌和面部手术中的控制性低血压。指出了在NLA、氟烷和安氟醚麻醉下,硝普钠引起的低血压各阶段之间的差异。硝普钠引起的初始低血压为-48%,同时心率增加33%。这取决于不同的麻醉方法。平均永久性低血压达到-36%所需的剂量在1.3至22.3微克/千克/分钟之间变化。结果证明,即使在不采用头高位且处于中度低血压状态下使用,硝普钠也能确保减少术野出血。与氟烷和安氟醚联合使用时,低血压比与NLA联合使用时更容易调节。然而,这常常导致心脏的频率负荷增加,因此常常不得不使用β-肾上腺素能阻滞剂。手术条件得到改善,未发生意外情况。新型制剂Nipruss具有组织和卫生方面的优势。